nasdaq:galt
|
106865
|
Apr 21st, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 20th, 2024 11:30PM
|
Apr 20th, 2024 11:30PM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 20th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 19th, 2024 11:27PM
|
Apr 20th, 2024 05:02PM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 19th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 18th, 2024 11:34PM
|
Apr 18th, 2024 11:34PM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 18th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 17th, 2024 11:42PM
|
Apr 18th, 2024 06:22PM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 17th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 16th, 2024 11:24PM
|
Apr 17th, 2024 02:47PM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 16th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 15th, 2024 11:20PM
|
Apr 16th, 2024 11:04AM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 15th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 14th, 2024 11:16PM
|
Apr 15th, 2024 04:44PM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 14th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 13th, 2024 11:05PM
|
Apr 13th, 2024 11:05PM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 13th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 12th, 2024 10:56PM
|
Apr 13th, 2024 11:31AM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:galt
|
106865
|
Apr 12th, 2024 12:00AM
|
Galectin Therapeutics
|
1.8K
|
41.00
|
Open
|
|
Apr 11th, 2024 11:01PM
|
Apr 12th, 2024 08:26AM
|
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.
We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
|
Open
|
|
Open
|
4960 Peachtree Industrial Boulevard
|
Norcross
|
GA
|
US
|
30071
|
|
Galectin Therapeutics
|
|
Health Care Equipment & Services
|